Generic name: LAMIVUDINE 300mg, TENOFOVIR DISOPROXIL FUMARATE 300mg
Dosage form: tablet, film coated
Drug class: Antiviral combinations
Medically reviewed by Drugs.com. Last updated on Feb 6, 2023.
Testing Prior to Initiation and During Treatment with CIMDUO
Prior to initiation of CIMDUO, test patients for hepatitis B virus infection [see Warnings and Precautions (5.2)].
It is recommended that serum creatinine, serum phosphorus, estimated creatinine clearance, urine glucose, and urine protein be assessed before initiating CIMDUO and during therapy in all patients as clinically appropriate [see Warnings and Precautions (5.3)].
Recommended Dosage for Adult and Pediatric Patients Weighing at Least 35 kg
CIMDUO is a two-drug fixed-dose combination product containing 300 mg of lamivudine (3TC) and 300 mg of tenofovir disoproxil fumarate (TDF). The recommended dosage of CIMDUO in HIV-1-infected adult and pediatric patients weighing at least 35 kg is one tablet taken orally once daily with or without food.
Not Recommended in Renal Impairment
Because CIMDUO is a fixed-dose combination tablet and cannot be dose adjusted, it is not recommended for patients with impaired renal function (creatinine clearance less than 50 mL/min) or patients with end-stage renal disease (ESRD) requiring hemodialysis [see Use in Specific Populations (8.6)].
Frequently asked questions
- How much does HIV treatment Cimduo cost?
- What is the difference between HIV treatments Symfi and Symfi Lo?
- What drugs are contained in the HIV treatment Cimduo?
More about Cimduo (lamivudine / tenofovir)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Imprints, shape & color data
- Side effects
- During pregnancy
- FDA approval history
- Drug class: antiviral combinations
- En español
Related treatment guides
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.